Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > The chat

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Feb 11, 2021 12:17pm

94 Views

Post# 32538688

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The chat

All R&D companies are high risk high reward yet they get decent valuation look at intercept with 17000 followers on Stocktwits versus THTX's 800! they have awful drug they were projected to be first company to get a NASH drug approved yet their phase 3 trial was rejected by FDA.
Their market valuation is still at multiples of THTX.
They corrected the analysts reports and still pushing to get their drug approved which if I remember it had fatal effects, how is that intercept with a lethal high risk drug and thanks to the failed phase 3 drug low potential reward get still credit for their program yet THTX has failed to be valued fairly?Again in my opinion the valuation gap is not based on risk/reward equation it is based on lack of convincing marketing to right segment of the market.
I believe the company now shares that view and if not they have to put up with my emails and phone calls.

jfm1330 wrote: Yes but the same Paul said just yesterday that Thera was still a high risk, high reward investment. What we tend to forget in high risk, high reward, there is the flip of the coin. Since high risk is involved in the these kind of investment the other possible outcome is high risk, no reward. Yes the potential is huge if it works.

scarlet1967 wrote: Point is Jim Paul said potential $$ revenues if the cancer trial is successful so investors get an idea about the value of their science only that without even understanding the science get the attention of mom and dad investors now they need to make sure more people get the message, broader audience "retail investors".

jfm1330 wrote: I never said otherwise, but even understanding Thera right now would not mean you would find investors to pay a lot more than the actual price.

Also, I said here after the financing, that even if the SP would have gone higher after the news of the FDA giving the green light to clinical trials, that does not mean a bought deal would have been possible at that higher price, let's say 5 or 6$ CAN. They needed to sell a lot a shares to get that deal done. I still don't buy the incompetence argument on that, even less the idea of a crooked deal.

scarlet1967 wrote: So we are in agreement that investors have to understand the potential of R&D programs scientific and financials.